Jazz Pharmaceuticals (JAZZ) Cut to “Sell” at Zacks Investment Research
Zacks Investment Research lowered shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a hold rating to a sell rating in a report issued on Tuesday morning.
According to Zacks, “Jazz lowered its earnings guidance for 2017, mainly due to lower-than-expected sales from Xyrem. Xyrem is facing patent challenges in the United States. Jazz has also been facing difficulties in building sufficient inventory levels for leukemia drug, Erwinaze, due to constrained manufacturing capacity. The company has its share of pipeline setback too. However, its lead pipeline candidate, JZP-110, currently evaluated for treatment of EDS, complements its existing sleep disorder portfolio. Nonetheless, the FDA approval of, Vyxeos in August, lends huge boost to the company, given its huge commercial potential in the target market. Shares of the company outperformed the industry so far this year.”
A number of other research analysts have also recently issued reports on the company. Royal Bank of Canada reaffirmed a buy rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, September 15th. UBS Group reaffirmed a buy rating and set a $172.00 price objective (down from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. Wells Fargo & Co reaffirmed an outperform rating and set a $172.00 price objective (down from $177.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, November 8th. BMO Capital Markets reaffirmed a buy rating and set a $196.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Mizuho raised their price objective on Jazz Pharmaceuticals from $144.00 to $150.00 and gave the company a neutral rating in a research note on Tuesday, December 5th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $181.68.
Shares of Jazz Pharmaceuticals (JAZZ) opened at $135.59 on Tuesday. Jazz Pharmaceuticals has a 12-month low of $112.52 and a 12-month high of $163.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10. The firm has a market capitalization of $8,197.63, a PE ratio of 17.16, a price-to-earnings-growth ratio of 0.74 and a beta of 0.98.
In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 352 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total transaction of $46,882.88. Following the sale, the director now directly owns 1,365 shares of the company’s stock, valued at approximately $181,804.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Patrick G. Enright sold 9,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.73, for a total value of $1,257,570.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,552 shares of company stock worth $2,399,643. Insiders own 4.30% of the company’s stock.
A number of institutional investors have recently bought and sold shares of JAZZ. Schwab Charles Investment Management Inc. boosted its position in Jazz Pharmaceuticals by 6.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 185,666 shares of the specialty pharmaceutical company’s stock valued at $28,872,000 after acquiring an additional 10,446 shares in the last quarter. First Trust Advisors LP bought a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $2,280,000. SG Americas Securities LLC boosted its position in Jazz Pharmaceuticals by 13.0% during the 2nd quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock valued at $215,000 after acquiring an additional 159 shares in the last quarter. Federated Investors Inc. PA boosted its position in Jazz Pharmaceuticals by 35.0% during the 2nd quarter. Federated Investors Inc. PA now owns 16,200 shares of the specialty pharmaceutical company’s stock valued at $2,519,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in Jazz Pharmaceuticals by 4.0% during the 2nd quarter. Victory Capital Management Inc. now owns 3,410 shares of the specialty pharmaceutical company’s stock valued at $530,000 after acquiring an additional 132 shares in the last quarter. 90.73% of the stock is currently owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.